B15-06 Tozorakimab, an Anti-IL-33 Antibody, Modulates Pathways Associated With Airway Inflammation and Tissue Dysfunction in COPD Patients: Mechanistic Evidence From FRONTIER-4
Randomized trial assesses the effect of tozorakimab on airway inflammation in COPD patients, suggesting broader implications for treatment.
Key Points
The research aims to evaluate the mechanistic effects of tozorakimab on pathways related to airway inflammation and tissue dysfunction in COPD patients.
Collected spontaneous sputum and serum samples from COPD patients in FRONTIER-4 at baseline, weeks 4, 12, and 28 after administering tozorakimab or placebo.
Analyzed samples using the Olink Explore HT proteomic platform to assess changes in biomarker concentrations.
Radomized trial with a dosing regimen of tozorakimab 600 mg subcutaneously every 4 weeks.
Tozorakimab reduced lymphotoxin beta (LTB) concentration by 19.1% at week 12 (unadjusted p=0.018) and 29.3% at week 28 (unadjusted p=0.001).
It also reduced proteoglycan 3 (PRG3) by 47.1% at week 12 (unadjusted p=0.039) and 65.7% at week 28 (unadjusted p=0.004).
Numerical reductions in biomarkers of eosinophilic inflammation and neutrophil activation were observed across all time points.